Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...